The European Commission has approved a new film-coated tablet formulation of Sino-American oncology-focused biotech BeOne Medicines’ Brukinsa (zanubrutinib) for all approved indications.

Russian drugmaker R-Pharm is searching buyers for its flagship factory in Germany in the city of Illertissen, which was ...

The US eosinophilic esophagitis (EoE) market is projected to grow from $202 million in 2020 to $1.19 billion in 2030, ...

Shares in Biohaven moved up about 7% on Friday after the company provided an update with respect to its New Drug Application (NDA) for troriluzole for the treatment of adult patients with ...

Dutch immunology company argenx has announced positive top-line data from the pivotal ADAPT SERON Phase III study of Vyvgart ...

Founded in 2016 and headquartered in San Francisco, Multiply Labs designs robotic manufacturing systems for personalized ...

The US Food and Drug Administration on Friday revealed it has begun daily publication of adverse event data from the FDA ...

The US Food and Drug Administration (FDA) granted approval for a second treatment for metabolic dysfunction-associated ...

Parexel has announced the appointment of Jim Anthony to the expanded role of chief commercial officer (CCO) and president of ...

Moderna today revealed that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikevax (elasomeran), targeting ...

The pharmaceutical industry and the UK government have failed to reach agreement on requested changes to a medicines payment ...

The range of drugs available in the Russian market may significantly decrease in the short term due to protectionist measures ...